Wearing-off Questionnaire as a quantify measure of Wearing-off
Objective: To aim for the correlation of 19- items Wearing Off Questionnaire (WOQ-19) positive items and MDS-UPDRS IV. Background: Parkinson's disease (PD) has a well…Parkinson’s patient insights, knowledge and experience of treatment – results from a multicountry survey
Objective: To understand the perceptions and knowledge that people with Parkinson’s disease (PD) have about their treatment, available options for advanced PD, and to determine…The effect of rasagiline on nocturnal hypokinesia: the analysis of the Nocturnal Hypokinesia Questionnaire (NHQ)
Objective: To identify the effect of rasagiline on nocturnal hypokinesia based on Nocturnal Hypokinesia Questionnaire (NHQ). Background: Nocturnal hypokinesia refers to the difficulty or the…Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa
Objective: To evaluate time to ON without troublesome dyskinesia (‘good ON’) and patterns of motor-state stability throughout the day in patients with advanced Parkinson’s disease…Understanding the continuing educational needs of US clinicians managing OFF episodes in Parkinson’s disease
Objective: This study sought to understand the continuing medical education (CME) needs of US-practicing neurologists (NEUROs) and neurology advanced practice providers (APPs) in managing patients with Parkinson’s Disease (PD) experiencing…Comparison of efficacy and safety of adjunct treatments to levodopa in patients with Parkinson’s disease and wearing-off: A network meta-analysis of randomized, double-blind trials
Objective: To determine the rankings for efficacy and tolerability of levodopa adjuncts in patients with Parkinson’s disease (PD) and wearing-off by network meta-analysis. Background: When…Opicapone use in patients with Parkinson’s disease with motor fluctuations: experience from a tertiary center
Objective: To assess effectiveness and safety profile of Opicapone in our cohort of patients with Parkinson’s disease (PD) who received this treatment. Background: Opicapone is…Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)
Objective: An analysis of the proportion of patients who turned ON after levodopa inhalation powder (CVT-301) 84mg treatment vs placebo, compared across subgroups of patients…Personalization of deep brain stimulation using local field potentials to drive adaptive DBS: a case series
Objective: To observe chronically recorded local field potentials (LFPs) in patients receiving Deep Brain Stimulation (DBS) for Parkinson’s Disease (PD) and using an adaptive DBS…Non-motor fluctuations in People with Parkinson’s considering Deep Brain Stimulation surgery
Objective: In this study we examine non-motor symptom (NMS) fluctuations reported by People with Parkinson’s (PWP) pursuing Deep Brain Stimulation (DBS) surgery using the MDS…
- « Previous Page
- 1
- …
- 3
- 4
- 5
- 6
- 7
- …
- 24
- Next Page »